Join Growin Stock Community!

昱厚生技6709.TW Overview

TW StockBiotech. & Medical
(No presentation for 6709)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

昱厚生技（6709）Overall Performance

昱厚生技（6709）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

昱厚生技（6709） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

昱厚生技（6709）Key Information

昱厚生技（6709）Profile

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. Its products in development include nasal spray influenza vaccine, allergy vaccines, and COVID-19 immunotherapy. The company is based in Taipei, Taiwan.

昱厚生技（6709）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.87
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.56
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
12.87
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6709

昱厚生技

33.00D

-0.15%

(-0.00)

  • When is 6709's latest earnings report released?

    The most recent financial report for 昱厚生技 (6709) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6709's short-term business performance and financial health. For the latest updates on 6709's earnings releases, visit this page regularly.

  • How much cash does 6709 have?

    At the end of the period, 昱厚生技 (6709) held Total Cash and Cash Equivalents of 55.33M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6709's EPS continuing to grow?

    According to the past four quarterly reports, 昱厚生技 (6709)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.59. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6709?

    昱厚生技 (6709)'s Free Cash Flow (FCF) for the period is 964K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.